BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  AstraZeneca Targets First-Line Mantle Cell Lymphoma Therapy with Phase III Data

  AstraZeneca’s blockbuster BTK inhibitor Calquence significantly improved progression-free survival when used as a frontline treatment in patients with mantle cell lymphoma, according to Thursday’s late-stage results.

  May 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Generative AI Finds Its Footing in Drug Development

  Since the 2022 launch of ChatGPT, biopharma has poured money into this new form of artificial intelligence, but companies remain cautious with unproven technology.

  May 3, 2024

   · 

  6 min read

   · 

  Neil Versel
• 

  Drug Development

  AAVs in Focus at ASGCT: Improved Precision, Targeting Common Diseases

  Adeno-associated viruses have long been go-to vectors for gene therapies. How AAVs are improving will be among the cell and gene therapy topics to be covered in Baltimore this week.

  May 3, 2024

   · 

  4 min read

   · 

  Mollie Barnes
• 

  Drug Development

  Novo Nordisk’s Wegovy Pricing Drops as Competition Heats Up with Eli Lilly

  It wasn’t calls from lawmakers but market competition with Eli Lilly’s Zepbound that prompted Novo Nordisk to lower the prices of its blockbuster weight-loss drug.

  May 3, 2024

   · 

  3 min read

   · 

  Greg Slabodkin
• 

  Drug Development

  BioSpace Heads to #ASGCT, Along with Thousands in Cell and Gene Therapy

  Follow News Editor Greg Slabodkin and Managing Editor Jef Akst as they travel with some 8,000 others for discussions of cell and gene therapy advances, challenges, regulations and more.

  May 3, 2024

   · 

  1 min read

   · 

  Greg Slabodkin, Heather McKenzie, Jef Akst
• 

  Drug Development

  Amgen Pushes Obesity Drug MariTide Forward, Reports 22% Q1 Revenue Growth

  Following strong Phase II data, Amgen is going all in on its next-generation obesity treatment MariTide, with plans to run a Phase III trial and a separate mid-stage study for diabetes.

  May 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Boehringer, Walgreens Team Up for Obesity Trial as Weight-Loss Drug Race Heats Up

  In an effort to improve diversity and accessibility in clinical trials, Boehringer Ingelheim is partnering with Walgreens to conduct a Phase III study in obesity and type 2 diabetes.

  May 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  ASGCT 2024 Comes at Pivotal Time for Gene and Cell Therapy Sector

  Jeffrey Chamberlain, president of the American Society of Gene & Cell Therapy, spoke with BioSpace about what we can expect to learn about in Baltimore this week.

  May 3, 2024

   · 

  6 min read

   · 

  Greg Slabodkin
• 

  Policy

  FDA’s Accelerated Approval of Sarepta DMD Gene Therapy Comes Under Fire

  Ahead of the FDA’s June target action date for Sarepta’s Duchenne muscular dystrophy gene therapy, ICER Chief Medical Officer David Rind blasted the regulator’s accelerated pathway in a JAMA viewpoint article.

  May 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Novo-Backed Reunion Raises $103M Series A Financing for Psychedelic Trial

  The New Jersey-based biopharma will use the funds to support a Phase II study of its serotonergic psychedelic drug candidate in postpartum depression.

  May 3, 2024

   · 

  2 min read

   · 

  Tyler Patchen